Mechanisms of resistance to xenobiotics in human therapy

Cellular and Molecular Life Sciences

Volumn 54, Issue 5, 1998, Pages 405-426

  Saves, I ^a   Masson, J M ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b INSA   (France)

Author keywords

Anti HIV 1 drugs; Antibiotic; Antipaludic drugs; Cytotoxic drugs; DNA repair; Drug detoxification; Drug inactivation; MDR

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; XENOBIOTIC AGENT;

DETOXIFICATION; DNA REPAIR; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; PHARMACOECONOMICS; PHARMACOLOGY; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HUMANS; METABOLIC DETOXICATION, DRUG; XENOBIOTICS;

EID: 0031836631     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050170     Document Type: Review

References (221)

1. Frei E., Rosovosky A., Wright J. E., Cucchi C. A., Lippke J. A., Ervin T. J. et al. (1984) Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc. Natl. Acad. Sci. USA 81: 2873-2877
2. Hromas R. A., North J. A. and Burns C. P. (1987) Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 36: 197-201
3. Sirotnak F. M., Yang C. H., Mines L. S., Orib E. and Biedler J. L. (1986) Markedly altered membrane transport and intracellular binding of vincristine in multidrug resistant chinese hamster cells selected for resistance to vinca alkaloids. J. Cell. Physiol. 126: 266-274
4. Skovsgaard T. (1978) Mechanism of cross resistance between vincristine and daunorubicine in Ehrlich ascites tumour cells. Cancer Res. 38: 4722-4727
5. Ling V. and Thompson L. H. (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83: 103-116
6. Carlsen S. A., Till J. E. and Ling V. (1976) Modulation of membrane drug permeability in Chinese hamster ovary cells. Biochim. Biophys. Acta 455: 900-912
7. Sanchez C. P., Wunsch S. and Lanzer M. (1997) Identification of a chloroquine importer in Plasmodium falciparum. Differences in import kinetics are genitically linked with the chloroquine-resistant phenotype. J. Biol. Chem. 272: 2652-2658
8. Nikaïdo H. (1994) Porins and specific diffusion channels in bacterial outer membranes. J. Biol. Chem. 269: 3905-3908
9. Van Alphen W. (1978) Pores in the outer membrane of Escherichia coli K12. Involvement of proteins b and c in the permeation of cephaloridine and ampicillin. FEMS Microbiol. Lett. 3: 103-106
10. Nikaïdo H. (1992) Porins and specific channels of bacterial outer menbrane. Mol. Microbiol. 6: 435-442
11. Quinn J. P., Dubek E. S., Divinceuzo C. A., Lucks D. A. and Lerner S. A. (1986) Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154: 289-294
12. Tzouvelekis L. S., Tzelapi E., Kaufmann H. E. and Mentis A. F. (1994) Consecutive mutation leading to the emergence in vivo of imipeneme resistance in a clinical strain of Enterobacter aerogenes. J. Med. Microbiol. 40: 403-407
13. Livingstone D., Gill M. J. and Wise R. (1995) Mechanism of resistance to carbapenemes. J. Antimicrob. Chemother. 35: 1-5
14. Cohen S. P., MacMurry L. and Levy S. B. (1988) Mar A locus causes decreased expression of Omp F porin in multiple antibiotic resistant (MAR) mutants of Escherichia coli. J. Bact. 170: 5416-5422
15. Rosner J. L., Chai T. J. and Foulds J. (1991) Regulation of ompF expression by salicylate in E. coli. J. Bact. 173: 5631-5638
16. Denis A. and Moreau N. J. (1993) Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and fluoroquinolone of various hydrophobicity, and analysis of membrane composition. J. Antimicrob. Chemother. 32: 379-382
17. Nikaïdo H. (1994) Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264: 382-388
18. Wiedemann B. and Heisig P. (1994) Mechanism of quinolone resistance. Infection 52: 573-579
19. Fralick J. A. and Burns-Keliher L. (1994) Additive effect of tolC and rfa mutations on the hydrophobic barrier of the outer membrane of E. coli K12. J. Bact. 176: 6404-6406
20. Hancock R. E. (1997) The bacterial outer membrane as a drug barrier. Trends Microbiol. 5: 37-42
21. Higgins C. F. (1992) ABC transporters: from microorganism to man. Annu. Rev. Cell Biol. 8: 67-113
22. Schinkel A. H., Mayer U., Wagenaar E., Mol C., van Deemter L., Smit J. J. M. et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94: 4028-4033
23. Bradley G., Juranka P. F. and Ling V. (1988) Mechanisms of multidrug resistance. Biochim. Biophys. Acta 948: 87-128
24. Endicott J. A. and Ling V. (1989) The biochemistry of p-glycoprotein mediated multidrug resistance. Ann. Rev. Biochem. 58: 137-171
25. Ford J. M. and Hait W. N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42: 155-199
26. Gottesman M. M. and Pastan I. (1993) Biochemistry of multidrug resistance mediated by multidrug transporter. Ann. Rev. Biochem. 62: 385-427
27. Goldstein L. J. (1995) Clinical reversal of drug resistance. Curr. Probl. Cancer 19: 65-124
28. Hyde S. C., Emsley P., Hartshorn M. J., Mimmack M. M., Gylaedi V., Pearce S. R. et al. (1990) Structural model of ATP binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346: 362-365
29. Roninson I. B., Chin J. E., Choi K., Gros P., Housman P., Fojo A. et al. (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. USA 83: 4538-4542
30. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J. and Ling V. (1985) Amplification of p-glycoprotein genes in multidrug resistant mammalian cell lines. Nature 316: 817-819
31. Goldstein L. J., Galski H., Fojo A., Willingham M. W., Lai S. L., Gazdar A. et al. (1989) Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81: 116-124
32. Ueda K., Cardarelli C., Gottesman M. M. and Pastan I. (1987) Expression of a full-length cDNA for human 'MDR-1' gene confers resistance to colchocine, doxorubicine and vinblastine. Proc. Natl. Acad. Sci. USA 84: 3004-3008
33. Khono K., Tanimura H., Sato S., Nakayama Y., Makino Y., Wada M. et al. (1994) Cellular control of human multidrug resistance 1 (mdr1) gene expression in absence and presence of gene amplification in human cancer cells. J. Biol. Chem. 269: 20503-20508
34. Shem D. W., Fojo A., Chin J. E., Roninson I. B., Richert N., Pastan I. and Gottesman M. M. (1986) Human multidrug resistant cell lines: increased mdr 1 expression can precede gene amplification. Science 232: 643-645
35. Ahmad S., Safa A. R. and Glazer R. I. (1994) Modulation of p-glycoprotein by protein kinase Ca in a baculovirus expression system. Biochemistry 33: 10313-10318
36. Grunicke H., Hofmann J., Utz I. and Uberall F. (1994) Role of protein kinases antitumour drug resistance. Ann. Hematol. 69: S1-S6
37. Germann U. A., Chambers T. C., Ambudkar S. V., Pastan I. and Gottesman M. M. (1995) Effect of phosphorylation of p-glycoprotein on multidrug resistance. J. Bioenerg. Biomembr. 27: 53-61
38. Germann U. A., Chambers T. C., Ambudkar S. V., Litcht T., Cardarelli C. O., Pastan I. et al. (1996) Characterization of phosphorylation-defective mutants of human p-glycoprotein expressed in mammalian cells. J. Biol. Chem. 271: 1708-1716
39. Gupta K. P., Ward N. E., Gravitt K. R., Bergman P. J. and O'Brian C. A. (1996) Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoyled protein kinase C-alpha pseudosubstrate peptide. J. Biol. Chem. 271: 2102-2111
40. Beltran P. J., Fan D., Fidler I. J. and O'Brian C. A. (1997) Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased p-glycoprotein phosphorylation. Biochem. Pharmacol. 53: 245-247
41. MacGrath T. and Center M. S. (1988) Mechanisms of multidrug resistance in HL60cells, evidence that a surface membrane protein distinct from p-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res. 48: 3959-3963
42. MacGrath T., Latoud C., Arnold S. T., Safa A. R., Feloted R. L. and Center M. S. (1989) Mechanisms of multidrug resistance in HL60 cells, analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 38: 3611-3616
43. Grant C. E., Valdimarsson G., Hipfner D. R., Almqvist K. C., Cole S. P. C. and Dealey R. G. (1994) Overexpression of multidrug resistance associated protein (MRP) increases resistance to natural products. Cancer Res. 54: 357-361
44. Zaman G. J. R., Flens M. J., Van Leusden M. R., De Haas M., Mulder H. S., Lankelma J. et al. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91: 8822-8826
45. Shen H., Paul S., Breuninger L. M., Ciaccio P. J., Laing N. M, Hell M. et al. (1996) Cellular and in vitro transport of glulathione conjugates by MRP. Biochemistry 35: 5719-5725
46. Paul S., Breuninger L. M., Tew K. D., Shen H. and Kruh G. D. (1996) ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc. Natl. Acad. Sci. USA 93: 6929-6934
47. Eijdems E. W., De Haas M., Coco-Martin J. M., Oltenheim C. P., Zaman O. J., Dauwerse H. G. et al. (1995) Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int. J. Cancer 60: 676-684
48. Tsuruo T., Ida H., Tsukaghoshi S. and Sakural Y. (1981) Overcoming of vincristine resistance in P.388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972
49. Slater L. M., Murray S. L., Wetzel M. W., Widson R. M. and DuVall E. M. (1982) Verapamil restoration of daunorubicin responsiveness in daunorubicin resistant Ehrlich ascites carcinoma. J. Clin. Invest. 70: 1131-1134
50. Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnen M., Roe D. J. et al. (1991) Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44-50
51. Rushing D. A., Raber S. A., Rodvold K. A., Piscitelli S. C., Plank G. S. and Tewksbury D. A. (1994) The effects of cyclosporin on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74: 834-841
52. Abbaszadegan M. R., Foley N. E., Gleason-Guzman M. C. and Dalton, S. (1996) Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int. J. Cancer 66: 506-514
53. Jaffrezou J. P., Herbert J. M., Levade T., Gau M. N., Chatelain P. and Laurent G. (1991) Reversal of multidrug resistance by channel blocker SR 33557 without photoaffinity labelling of p-glycoprotein. J. Biol. Chem. 266: 19858-19864
54. Hyafil F., Vergely C., du Vignaud P. and Grand-Perret T. (1993) In vitro and in vivo reversal of multidrug resistance by GF120918 an acridonecarboxamide derivative. Cancer Res. 53: 4595-4602
55. Hait W. N., Gesmonde J. K, Murren J. R., Yang J. M., Chen H. X. and Reiss M. (1993) Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol. 45: 401-406
56. Fridborg H., Jonsson B., Nygnen P., Csoku K., Nilsson K., Oberg G. et al. (1994) Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br. J. Cancer 70: 11-17
57. Helson C., Zhahn Z. und Helson L. (1994) Reversion of p-glycoprotein mediated multidrug resistance to vincristine and adriamycin by PSC-833, a cyclosporin derivative in human neuroblastoma cell lines. Int. J. Oncol. 5: 1037-1042
58. Kirk J., Syed S. K., Harrio A. L., Jarman M., Roufogalis B. D., Stratford I. J. et al. (1994) Reversal of p-glycoprotein mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem. Pharmacol. 48: 277-285
59. Naïto M. and Tsuruo T. (1989) Competitive inhibition by verapamil of ATP-dependant high affinity vincristine binding to the plasma membrane of multidrug-resistant K cells without calcium ion involvement. Cancer Res. 49: 1452-1455
60. Shirai A., Naïto M., Tatoula T., Dong J., Hanaoka K., Mikami K. et al. (1994) Transport of cyclosprin A across the brain capillary endothelial cell monolayer by p-glycoprotein. Biochim. Biophys. Acta 1222: 400-404
61. Muller C., Goubin F., Ferrandis E., Cornil-Schwartz I., Bailly J. D., Bordier C. et al. (1995) Evidence for transcriptionnal control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol. Pharmacol. 47: 51-56
62. Herzorg C. E., Tsokos M., Bates S. E. and Fojo A. T. (1993) Increased mdr-1 P-glycoprotein expression after treatment of human colon carcinoma cells with p-glycoprotein antagonists. J. Biol. Chem. 268: 2946-2952
63. Kessel D. (1986) Interaction among membrane transport systems: anthracyclins, calcium antagonists and antiestrogens. Biochem. Pharmacol. 35: 2825-2826
64. Germann U. A., Ford P. J., Shlyakther D., Mason V. S. and Harding M. W. (1997) Chemosensitization and drug accumulation effects of VX-710: verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60 ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drug 8: 141-155
65. Stewart A. J., Canitrot Y., Baracchini E., Dean N. M., Deeley R. G. and Cole S. P. (1996) Reduction of expression of the multidrug resistance protein (MRP) in human tumour cells by antisense phosphorothioate oligonucleotides. Biochem. Pharmacol. 51: 461-469
66. Cucco C. and Calabretta B. (1996) In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 56: 4332-4337
67. Foley M. and Tilley L. (1997) Quinoline antimalarials: mechanisms of action and resistance. Int. J. Parasitol. 27: 231-240
68. Karcz S. and Cowman A. F. (1991) Similarities and differences between the multidrug resistance phenotype of mammalian tumour cells and chloroquine resistance in Plasmodium falciparum. Exp. Parasitol. 73: 233-240
69. Cowman A. F., Karcz S., Galatis D. and Culvenor J. G. (1991) A p-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J. Cell Biol. 113: 1033-1042
70. Foote S. J., Thompson J. K., Cowman A. F. and Kemp D. J. (1989) Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of Plasmodium falciparum. Cell 57: 921-930
71. Barnes D. A., Foole S. J., Galatis D., Kemp D. J. and Cowman A. F. (1992) Selection for high level chloroquine resistance results in deamplitication of the pfmdr-1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 11: 3067-3075
72. Wellems T. H., Panton L. J., Gluzman I. Y., do Rosario V. E., Gwadz R. W., Walker-Jonah A. et al. (1990) Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345: 253-255
73. Foote S. J., Kyle D. E., Martin R. K., Oduala A. M. J., Forsyth K., Kemp D. J. and Cowman A. F. (1990) Several alleles of the multidrug resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345: 255-258
74. Martin S. K., Oduala A. M. J. and Milhous W. K. (1987) Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235: 899-901
75. Ouelelte M. and Borst P. (1991) Drug resistance and p-glycoprotein gene amplification in the protozoan parasite Leishmania. Res. Microbiol. 142: 737-746
76. Légaré D., Hettema E. and Ouelette M. (1994) The p-glycoprotein related gene family in Leishmania. Mol. Biochem. Parasitol. 68: 81-91
77. Jenkinson H. F. (1996) Ins and outs of antimicrobial resistance: era of the drug pumps. J. Dent. Res. 75: 736-742
78. Lewis K. (1994) Multidrug resistance pumps in bacteria: variation on a theme. TIBS 19: 119-123
79. Li X. Z., Livermore D. M. and Nikaido H. (1994) Role of efflux pump(s) in intrinsic resistance of Pseudonomas aerugirosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob. Agents Chemother. 38: 1732-1741
80. Speer B. S., Shoemaker N. B. and Salyers A. A. (1992) Bacterial resistance to tetracycline: mechanism, transfer and clinical significance. Clin. Microbiol. Rev. 5: 387-399
81. Roberts M. C. (1994) Epidemiology of tetracycline-resistance determinants. Trends Microbiol. 2: 353-357
82. Rothstein D. M., McGlynn M., Bernan V., McGahren J., Zaccardi J., Cetkleniak N. et al. (1993) Detection of tetracyclines and efflux pump inhibitors. Antimicrob. Agents Chemother. 37: 1624-1629
83. Guay G. G., Tuckman M. and Rothstein D. M. (1994) Mutations in the tetA (B) gene that cause a change in substrate specificity. Antimicrob. Agents Chemother. 38: 857-860
84. + antiporter of Escherichia coli and the effects of amino acid substitution at the first site. Biochemistry 34: 7-12
85. Yoshida H., Bogaki M., Nakamura S., Ubukata K. and Khono M. (1990) Nucleotide sequence and characterization of S. aureus norA gene, which confers resistance to quinolones. J. Bact. 172: 6942-6949
86. Ross J. I., Eady E. A., Cove J. H., Cunliffe W. J., Baumberg S. and Wootton J. C. (1990) Inducible erythromycin resistance in Staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol. Microbiol. 4: 1207-1214
87. MacMurry L. M., George A. M. and Lewy S. B. (1994) Active efflux of chloramphenicol in susceptible Escherichia coli strains and in mutiple-antibiotic-resistant (Mar) mutants. Antimicrob. Agents Chemother. 38: 542-546
88. Sognier M. A., Zhang Y., Eberle R. L., Sweet K. M., Altenberg G. A. and Belli J. A. (1994) Sequestration of doxorubicin in vesicles in a multidrug resistant cell line (LZ-100), Biochem. Pharmacol. 48: 391-401
89. Dietel M., Arps H., Lage H. and Niendorf A. (1990) Membrane vesicle formation due to acquired mithoxanthrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50: 6100-6106
90. Cornwell M. M., Safa A. R., Felsted R. L., Gottesman M. M. and Pastan I. (1986) Membrane vesicles from multidrug resistant human cancer cells contain a specific 150-to 170-kDa protein detected by photoaffinity labelling. Proc. Natl. Acad. Sci. USA 83: 3847-3850
91. Horio M., Gottesman M. M. and Pastan I. (1988) ATP dependant transport of vinblastine in vesicles from human multidrug resistant cells. Proc. Natl. Acad. Sci. USA 85: 3580-3584
92. Ahmad S., Okine L., Le B., Najarian P. and Vistica D. T. (1987) Elevation of glutathione in phenylalanine mustard resistant murine L1210 leukemia cells. J. Biol. Chem. 262: 15048-15053
93. Puchalski R. B. and Fahl W. E. (1990) Expression of recombinant glutathione-S-transferase Π, Πa or Πb confers resistance to alkylating agents. Proc. Natl. Acad. Sci. USA 87: 2443-2447
94. Kelley V. K., Engqvist-Goldstein A., Montali, J. A., Wheatley J. B., Schmidt, D. E. and Kauvar Jr L. M. (1994) Variability of glutathione-S-transferase isoenzyme patterns in matched normal and cancer human breast tissue. Biochem. J. 304: 843-848
95. Dirven H. A., Dictus E. L., Broeders N. L., van Ommen B. and van Bladeren P. J. (1995) The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of alkylating cytostatic drug thiotepa. Cancer Res. 55: 1701-1706
96. Ali-Osman F., Stein D. and Renwick A. (1990) Glutathione content and glutathione-S-transferase expression in 1,3-Bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res. 50: 6976-6980
97. Nakagawa K., Saijo N., Tsuchida S., Sakai M., Tsunokawa Y., Yocota J. et al. (1990) Glutathione-S-transferase π as a determinant of drug resistance in transfectant cell lines. J. Biol. Chem. 265: 4296-4301
98. Skovsgaard T., Nielsen D., Maare C. and Wassermann K. (1994) Cellular resistance to cancer chemotherapy. Int. Rev. Cytology 156: 77-157
99. Lai G. M., Ozols R. F., Young R. C. and Hamilton T. C. (1989) Effect of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines. J. Natl. Cancer. Inst. 81: 535-539
100. Smith M. T., Evans C. G., Doane-Setzer P., Castro V. M., Tahir M. K. and Mannervik B. (1989) Denitrosation of 1,3-Bis(2-chloroethyl)-1-nitrosourea by class Mu glutathionetransferases and its role in cellular resistance in rat brain tumour cells. Cancer Res. 49: 2621-2625
101. Cole S. P. C., Downes H. F., Mirski S. E. L. and Clements D. J. (1990) Alterations in glutathione and glutathione related enzymes in a multidrug resistant small cell lung cancer cell line. Mol. Pharmacol. 37: 192-197
102. Janot F., Massaad L., Ribnag V., de Waziers I., Beaune P. H., Luboinski B. et al. (1993) Principal xenobiotic metabolizing enzyme systems in human head and neck squamous cell carcinoma. Cancer Res. 53: 1279-1283
103. Hao X. Y., Bergh J., Brodin O., Hellman U. and Mannervick B. (1994) Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 15: 1167-1173
104. Kramer R. A., Zalcher J. and Kim G. (1988) Role of glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697
105. Leier I., Jedlitschky G., Buchhol U., Cole S. P. C., Deeley R. G. and Keppler D. (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269: 27807-27810
106. Hansson J., Berhane K., Castro V. M., Jungnelius U., Mannervick B. and Ringborg U. (1991) Sensitization of human melanoma cells to cytotoxic effect of melphalan by the glutathione-transferase inhibitor ethacrynic acid. Cancer Res. 51: 94-98
107. Hall A., Robson C. N., Hickson I. D., Harris A. L., Proctor S. J. and Cattan A. R. (1989) Possible role of inhibition of GST in the partial reversal of chlorambucil resistance by indomethacin in a Chinese hamster ovary cell line. Cancer Res. 49: 6265-6268
108. Ploemen J. H. T. M., Van Schanke A., Van Ommen B. and Van Bladeren P. J. (1994) Reversible conjugation of ethacrynic acid with glutathione and human glutathione-S-transferase PI-1. Cancer Res. 54: 915-919
109. O'Dwyer P. J., La Creta F., Nash S., Tinsley P. W., Schilder R., Clapper M. L. et al. (1990) Phase I study of thiotepa in combination with the glutathione-transferase inhibitor ethacrynic acid. Cancer Res. 50: 6059-6065
110. Tew K. O., Bamber A. M. and Hoffman S. J. (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res. 48: 3622-3625
111. Berger S. J., Gosky D., Zborowska E., Willson J. K. V. and Berger N. A. (1994) Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthione sulfoximine in vivo and in vitro in human colon cancer. Cancer Res. 54: 4077-4083
112. Pommier Y., Leteurtre F., Fesen M. L., Fujimori A., Bertrand R., Solary E. et al. (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542
113. Vassetzky Y. S., Alghisi G. C. and Gasser S. M. (1995) DNA topoisomerase II mutations and resistance to anti-tumour drugs. Bioessays 17: 767-774
114. Pommier Y., Schwartz R. E., Zwelling L. A., Kerrigan D., Matten M. R., Charcosset J. Y. et al. (1986) Reduced formation of protein-associated DNA strand breaks in Chinese Hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 46: 611-616
115. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E. et al. (1989) Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug resistant form of topoisomerase II. J. Biol. Chem. 264: 16411-16420
116. Cole S. P. C., Chanda E. R., Dicka F. P., Gerlach J. H. and Mirski S. E. L. (1991) Non-p-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for a decreased succeptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 51: 3345-3352
117. Robinson M. J., Martin B. A., Gootz T. D., McGuirk P. R., Moynihan M., Sutcliffe J. A. et al. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II: a novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem. 266: 14585-14592
118. Beidler D. R. and Cheng Y. C. (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47: 907-914
119. Andoh T. and Odaka K. (1994) Drug resistance mechanisms of topoisomerase I drugs. Adv. Pharmacol. 29B: 93-103
120. Cowman A. F., Morry M. J., Biggs B. A., Cross G. A. M. and Foote S. J. (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidilate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 85: 9019-9113
121. Peterson D. S., Walliker D. and Wellems T. H. (1988) Evidence that a point mutation in dihydrofolate reductase-thymidilate synthase confers resistance to pyrimethamine in Falciparum malaria. Proc. Natl. Acad. Sci. USA 85: 9114-9118
122. Foote S. J., Galatis D. and Cowman A. F. (1990) Amino acids in the dihydrofolate reductase-thymidilate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 87: 3014-3017
123. Cheng Q. and Saul A. (1994) The dihydrofolate reductase domain of rodent malarias: point mutations and pyrimethamine resistance. Mol. Biochem. Parasitol. 65: 361-363
124. Sirawaraporn W., Sathitkul T., Sirawaraporn R., Yuthavong Y. and Santi D. V. (1997) Antifolate-resistant mutants of Plasmodium falciparum dehydrofolale reductase. Proc. Natl. Acad. Sci. USA 94: 1124-1129
125. Basco L. K., Eidin de Escoulas P., Wilsom C. M., LeBras J. and Mazabraud A. (1995) Point mutations in the dihydrofolate reduclase thymidilate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69: 135-138
126. Kimberlin D. W., Coen D. M., Biron K. K., Cohen J. I., Lamb R. A., McKinlay M. et al. (1995) Molecular mechanisms of antiviral resistance. Antiviral Res. 26: 369-401
127. Najera I., Richman D. D., Olivares I., Rojas J. M., Peinado M. A., Peruchon M. et al. (1994) Natural occurence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type I isolate. AIDS Res. Hum. Retroviruses 10: 1479-1488
128. Larder B. A. and Kemp S. D. (1989) Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 246: 1155-1158
129. Fischl M. A., Richman D. D., Causey D. M., Grieco M. H., Brison Y., Mildvan D. et al. (1989) Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 262: 2405-2410
130. Larder B., Kemp S. D. and Harrigan P. R. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699
131. Larder B. A., Darby G. and Richman D. D. (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734
132. Kellam P., Boucher C. A. and Larder B. A. (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89: 1934-1938
133. Brun-Vézinet F. (1997) Resistance aux antirétroviraux: les données du congrès de Whistler. ANRS Information 20: 38-42
134. St. Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M. et al. (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557-1559
135. Mac Leod G. X., Mac Grath J. M., Ladd E. A. and Hammer S. M. (1992) Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob. Agents Chemother. 36: 920-925
136. Ueno T., Shirasaka T. and Mitsuya H. (1995) Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleosidc 5′-triphosphates. J. Biol. Chem. 270: 23605-23611
137. Sharer R. W., Iversen A. K., Winters M. A., Aguinigua E., Katzenstein D. A. and Merigan T. C. (1995) Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS clinical trials group 143 virology team. J. Infect. Dis. 172: 70-78
138. Richman D., Shih C. K., Lowy I., Rose J., Prodanovitch P., Goff S. et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleosidc inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88: 11241-11245
139. Mellors J. W., Dutschman G. E., Im G. J., Tramontane E., Winkler S. R. and Cheng Y. C. (1992) In vitro selection and molecular characterization of human immunodeficiency virus 1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41: 446-451
140. Larder B. A. (1992) 3′-azido-3′ deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleosidc reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36: 2664-2669
141. Sardana V. V., Emini E. A., Gotlib L., Graham D. J., Lineberg D. W., Long W. J. et al. (1992) Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 267: 17526-17530
142. Declercq E. (1994) How to overcome resistance of HIV-1 to HIV-1 specific reverse transcriptase inhibitors. AIDS 8: 1020-1021
143. Declercq E. (1994) Resistance of human immunodeficiency virus type I (HIV-1) to nonnucleosidc HIV-1 specific reverse transcriptase inhibitors. Int. J. Immunother. 145-158
144. Condra J. H., Schleif W. A., Blahy O. M., Gadryelski L. J., Graham D. J., Quintero J. C. et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571
145. Chen Z., Li Y., Schock H. B., Hall D., Chen E. and Kuo L. C. (1995) Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270: 21433-21436
146. Eberle J., Bechowsky B., Rose D., Hauser U., von der Helm K., Gurtler L. et al. (1995) Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11: 671-676
147. Mustaev A., Zaychikov E., Severinov K., Kashlev M., Polyakov A., Nikiforov V. et al. (1994) Topology of the RNA polymerase active center probe by chimeric rifampicin-nucleotide compounds. Proc. Natl. Acad. Sci. USA 91: 12036-12040
148. Severinov K., Soushko M., Goldfarb A. and Nikiforov V. (1993) Rifampicin region revisited. J. Biol. Chem. 268: 14820-14825
149. Telenti A., Imbadeu P., Marchesi F., Lowrie D., Cole S., Colston J. et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650
150. Cole S. T. (1994) Mechanisms of drug resistance in Mycobacterium tuberculosis. Immunobiology 191: 584-585
151. Zhang Y. and Young D. (1994) Molecular genetics of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 34: 313-319
152. Quemard A., Sacchetini J. C., Dessen A, Vilcheze C., Bittman R., Jacobs W. R. et al. (1995) Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34: 8235-8241
153. Banarjee A., Dubrau E., Quemard A., Balaoubramanian V., Um K. S., Wilson T. et al. (1994) Inh A, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230
154. Drlica K. and Zhao X. (1997) DNA Gyrase, topoisimerase IV and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377-392
155. Hooper D. C. (1995) Quinolone mode of action. Drugs 49 S2: 10-15
156. Manukata N., Morohoshi F., Saitou M., Yamazaki N. and Hayashi K. (1994) Molecular characterization of thirteen gyrA mutations conferring nalidixic acid resistance in Bacillus subtilis. Mol. Gen. Genet. 244: 97-103
157. Tokua Y., Sugano K., Saito D., Noda T., Ohkura H., Shimasota Y. et al. (1994) Detection of novel mutations in the gyrA gene of S. aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. Antimicrob. Agents Chemother. 38: 428-431
158. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H. and Nakamura S. (1994) Quinolone resistance mutations in the DNA gyrase GyrA and GyrB genes of S. aureus. Antimicrob. Agents Chemother. 38: 2014-2023
159. Vila J., Ruiz J., Marco F., Barcelo A., Goni P., Giralt E. et al. (1994) Association between double mutation in GyrA gene of ciprofloxacin-resistant clinical isolate of E. coli and MIC. Antimicrob. Agents Chemother. 38: 2477-2479
160. Deguchi T., Fukuoka A., Yasuda M., Nakano M., Ozeki S., Katematsu E. et al. (1997) Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41: 699-701
161. Heisig P. (1996) Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40: 879-885
162. Tankovic J., Perichon B., Duval J., and Courvalin P. (1996) Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vitro and in vivo. Antimicrob. Agents Chemother. 40: 2505-2510
163. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A. et al. (1994) Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13: 641-653
164. Yamagishi J., Kojima T., Oyamada Y., Fujimoto K., Hattori H. et al. (1996) Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 1157-1163
165. Dam M., Douthwaite S., Tenson T. and Mankin A. S. (1996) Mutations in domain II of 23S rRNA facilitate translation of a 23S rRNA-encoded pentapeptide conferring erythromycin resistance. J. Mol. Biol. 259: 1-6
166. Weisblum B. (1985) Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression: a review. J. Antimicrob. Chemother. 16: 63-90
167. Leclercq R. and Courvalin P. (1991) Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 35: 1267-1272
168. Frère J. M., Joris B., Granier B., Matagne A., Jacob F. and Bourguignon-Bellefroid C. (1991) Diversity of the mechanism of resistance to β-lactam antibiotics. Res. Microbiol. 142: 705-710
169. Spratt B. G. (1978) Escherichia coli resistance to β-lactam antibiotics through a decrease in the affinity of a target for lethality. Nature 274: 713-715
170. Chambers H. F., Sachdera M. J. and Dackbarth C. J. (1994) Kinetics of penicillins binding to penicillin binding proteins of Staphylococcus aureus. Biochem. J. 301: 139-144
171. Tomasz A. (1994) Benefit and risk in the β-lactam antibiotic-resistance strategies of Streptococcus pneumoniae and Staphylococcus aureus. Trends Microbiol. 2: 380-385
172. Smith A. M., Klugman K. P., Coffrey T. S. and Spratt B. G. (1993) Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob. Agents Chemother. 37: 1938-1944
173. Smith A. M. and Klugman K. P. (1995) Alterations in penicillin-binding-protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 39: 859-867
174. Klare I., Rodloff A. C., Wagner J., Witte W. and Hakeubeck R. (1992) Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 36: 783-787
175. Fontana R., Aldegheni M., Ligozzi M., Lopez H., Sucari A. and Satta G. (1994) Overproduction of a low affinity penicillin binding protein and high level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 38: 1980-1983
176. Berger-Bächi B. (1994) Expression of resistance to methicillin. Trends Microbiol. 2: 389-393
177. Ryffel C., Strassle A., Kayser F. H. and Berger-Bächi B. (1994) Mechanism of heteroresistance in methicillin-resistant S. aureus. Antimicrob. Agents Chemother. 38: 724-728
178. Spera R. V. and Farber B. F. (1994) Multidrug resistant Enterococcus faecium, an untreatable nosocomial pathogen. Drugs 48: 678-688
179. Arthur M. and Courvalin P. (1993) Genetics and mechanisms of glycopeptide resistance in Enterococci. Antimicrob. Agents Chemother. 37: 1563-1571
180. Bugg T. D. H., Dutka-Malen S., Arthur M., Courvalin P. and Walsh C. T. (1991) Identification of vancomycin resistance protein Van A as a D-Ala-D-Ala ligase of altered substrate specificity. Biochemistry 30: 2017-2020
181. Schlaes D. M. and Rice L. B. (1994) Bacterial resistance to the cyclic glycopeptides. Trends Microbiol. 2: 385-388
182. Wu Z., Wright G. D. and Walsh C. T. (1995) Overexpression, purification and characterization of Van X, a D-,D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 34: 2455-2463
183. Arthur M., Depardieu F., Snaith H. A., Reynolds P. E. and Courvalin P. (1994) Contribution of Van Y DD-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob. Agents Chemother. 38: 1899-1903
184. Reynolds P. E, Snaith H. A., Maguire A. J., Dutka-Malen S. and Courvalin P. (1994) Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum. Biochem. J. 301: 5-8
185. Darby G., Field J. and Salbury S. A. (1981) Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir resistance. Nature 289: 81-83
186. Coen M. D. (1991) The implication of resistance to antiviral agents for herpes virus drug targets and drug therapy. Antiviral Res. 15: 287-300
187. Heym B., Alzani P., Honore N. and Cole S. T. (1995) Missense mutations in the catalase-peroxydase gene, KatG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15: 235-245
188. Rouse D. A. and Morris S. L. (1995) Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mvcobacterium bovis. Infect. Immun. 63: 1427-1433
189. Sherman D. R., Mdluli K., Hickey M. J., Arain T. M., Morris S. L., Barry C. E. et al. (1996) Compensatory aphC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641-1643
190. Scorpio A. and Zhang Y. (1996) Mutations in pncA, a gene encoding for pyrazinamidase, nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2: 662-667
191. Zhang Y., Sweet K. M., Sognier M. A. and Belli J. A. (1992) An enhanced ability for transforming adriamycin into a noncytotoxic form in a multidrug resistant cell line (LZ8). Biochem. Pharmacol. 44: 1869-1877
192. Metha K. (1994) High levels of transglutaminase expression in doxorubicin-resitant human breast carcinoma cells. Int. J. Cancer 58: 400-406
193. Davies J. (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science 264: 375-382
194. Frère J.-M. (1995) β-lactamases and bacterial resistance to antibiotics. Mol. Microbiol. 16: 385-395
195. Jacoby G. A. and Medeiros A. A. (1991) More extended spectrum β-lactamases. Antimicrob. Agents Chemother. 35: 1697-1704
196. Jacoby G. (1994) Genetics of extended spectrum β-lactamase. Eur. J. Clin. Microbiol. Inf. Dis. S1: 2-11
197. Petit A., Mavcyraud L., Lenfant F., Samama J.-P., Labia R. and Masson J.-M. (1995) Multiple substitutions at position 104 of β-lactamase THM-1: assessing the role of this residue in substrate specificity. Biochem. J. 305: 33-44
198. Saves I., Burlet-Schiltz O., Maveyraud L., Samama J.-P., Promé J.-C. and Masson J.-M. (1995) Effect of glycine to serine substitution at the position 238 of β-lactamase TEM-1 on acylation and deacylation during the hydrolysis of penicillins and cefotaxime. Biochemistry 34: 11660-11667
199. Maveyraud L., Saves I., Burlet-Schiltx O., Swaren P., Masson J.-M., Delaire M. et al. (1996) Structural basis of extended-spectrum β-lactamase: crystallographic, electrostatic, kinetic and mass spectrometric investigations of enzyme mutants. J. Biol. Chem. 271: 10482-10489
200. Masterton R. G., Garner P. J., Harrison N. A. and Rainford D. J. (1987) Timentin resistance. Lancet 2: 975-976
201. Thomson C. J. and Amyes S. G. B. (1992) TRC-1: emergence of a clavulanic acid resistant TEM β-lactamase in a clinical strain. FHMS Microbiol. Lett. 91: 113-118
202. Stapleton P., Wu P. J., King A., Shannon K., French G. and Phillips I. (1995) Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39: 2478-2483
203. Delaire M., Labia R., Samama J.-P. and Masson J.-M. (1992) Site directed mutagenesis at the active site of E. coli TFM-1 β-lactamase. J. Biol. Chem. 267: 20600-20606
204. Saves I., Burlet-Schiltz O., Swarèn P., Lefevre F., Masson J.-M., Promé L-C. and Samama J.-P (1995) The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-laclamase resistance to clavulanic acid. J. Biol. Chem. 270: 18240-18245
205. Shaw K. J., Rather P. N., Hare R. S. and Miller G. H. (1993) Molecular genetics of aminoglycoside resistance genes and familial relationship of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57: 138-163
206. Roestamadji J., Grapsas I. and Mobashery S. (1995) Mechanism-based inactivation of bacterial aminoglycoside 3′phosphotransferases. J. Am. Chem. Soc. 117: 80-84
207. Shaw W. V. (1984) Bacterial resistance to chloramphenicol. Br. Med. Bull. 40: 36-41
208. Yazawa K., Mirami Y., Sakamoto T., Ueno Y., Morisaki N., Iwasaki S. et al. (1994) Inactivation of the macrolide antibiotics erythromycin, midecamycin and rokitamycin by pathogenic nocardia species. Antimicrob. Agents Chemother. 38: 2197-2199
209. Rende-Fournier R., Leclereq R., Galimand M., Duval J. and Courvalin P. (1993) Identification of the SatA gene encoding a streptogramin A acelyltransferase in Enterococcus faecium BM4145. Antimicrob. Agents Chemother. 37: 2119-2125
210. von Der Haar B. and Schrempf M. (1995) Purification and characterisation of a novel extracellular Streptomyces lividaus 66 enzyme inactivating fusidic acid. J. Bact. 177: 152-155
211. Dabbs E. R., Yazawa K., Mirami Y., Miyaji M., Morisaki N., Imasaki S. et al. (1995) Ribosylation by mycobacterial strains as a new mechanism of rifampicin inactivation. Antimicrob. Agents Chemother. 39: 1007-1009
212. Andersen S. J., Quan S., Gowan B. and Dabbs E. R. (1997) Monooxygenase-like sequence of a Rhodocuccus equi gene conferring increased resistance to rifampicin by inactivating this antibiotic. Antimicrob. Agents Chemother. 41: 218-221
213. von der Haar B., Walter S., Schapenheuer S. and Schrempf H. (1997) A novel fusidic acid resistance gene from Streptomyces lividans 66 encodes a highly specific esterase. Microbiology 143: 867-874
214. Ali-Osman F., Rair Kar A. and Young P. (1995) Formation and repair of 1,3-bis(2-chloroethyl)-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. Cancer Biochem. Biophys. 14: 231-241
215. Chao C. C. K. (1994) Decreased accumulation as a mechanism of resistance to cis-diaminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair. Mol. Pharmacol. 45: 1137-1144
216. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50: 6119-6129
217. 6alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. Biochem. Pharmacol. 48: 543-548
218. 6-ethylguanine in DNA: relation to chemosensitivity in vitro and treatment outcome. Cancer Res. 54: 4524-4531
219. Naegeli H. (1994) Roadblocks and detours during DNA replication: mechanisms of mutagenesis in mammalian cells. Bioessays 16: 557-564
220. Yang L. Y., Li L., Keating M. J. and Plunkett W. (1995) Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol. 47: 1072-1079
221. Jain R. (1994) La difficile pénétration des médicaments dans les tumeurs. Pour la science 203: 56-63